3-D Matrix Ltd. engages in the research, development, manufacture, and sale of medical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 114 full-time employees. The company went IPO on 2011-10-24. Its Medical Products Business consists of the development and sales of medical products. Based on self-assembling peptide technology, it conducts research and development of medical devices and pharmaceuticals in the surgical, tissue regeneration, and drug delivery system (DDS) fields. Major development pipelines include absorbable topical hemostatic agents, mucosal elevation agents, post-bleeding prevention agents, next-generation hemostatic agents, and adhesion prevention agents in the surgical field, wound healing agents and alveolar bone reconstruction agents in the tissue regeneration field, and DDS for nucleic acid drugs in the DDS field.